NCT00258310View on ClinicalTrials.gov

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Head and Neck Cancer
Interventions
DRUG

capecitabine

Capecitabine 1000mg/day for one year

PROCEDURE

Surgery, chemotherapy and/or radiotherapy

Surgery, chemotherapy and/or radiotherapy

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00258310 - Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo | Biotech Hunter | Biotech Hunter